“Gilead Sciences” biopharmaceutical company exerts considerable efforts around the world to ensure that every patient with Hepatitis С, regardless of the country and financial status, had access to treatment.
Combination of sofosbuvir and ledipasvir, approved in 2015 in the USA and the EU, is available now in Ukraine in the form of the original innovation medicinal product HARVONI of “Gilead Sciences”, marketed in the pharmaceutical market of Ukraine and CIS countries by Delta Medical company.
HARVONI transformed Hepatitis C treatment as the first cure that’s one pill, once a day. There’s no interferon, no complex regimens. In clinical studies, 96-99% of patients with Hep C genotype 1 who had no prior treatment were cured with just 12 weeks of therapy.
With SOVALDI, there is a hope that you can put Hepatitis C behind you. SOVALDI is revolution medicine used to treat chronic (lasting a long time) hepatitis C genotype 1, 2, 3, or 4 infection in adults. Patients may be able to stop thinking about the disease, take the next step, and set a new course.
Patients from Kyrgyzstan already have access to HARVONI.
HARVONI launch in Ukraine is scheduled for February 3, 2017.
In other CIS countries, the products will be launched in 2017-2018.